β-NETA intermediate
|
3-(二甲基氨基)-1-(2-萘)-1-丙酮
|
2752-87-6
|
β-NETA
|
2-(BETA-萘甲酰基)乙基三甲基碘化銨
|
31059-54-8
|
Krass intermediate 01
|
KRAS中間體
|
2936672-10-3
|
Milrinone impurity Z10
|
米力農(nóng)Z10
|
2153433-47-5
|
Milrinone impurity Z06
|
米力農(nóng)Z06
|
80442-07-5
|
Milrinone impurity Z12
|
米力農(nóng)Z12
|
6302-02-9
|
Milrinone impurity Z09
|
米力農(nóng)Z09
|
156033-07-7
|
RO5166017
|
化合物 T34373
|
1048346-74-2
|
Tolterodine impurity Z10
|
托特羅定Z10
|
848768-06-9
|
Tolterodine impurity Z14
|
托特羅定Z14
|
1380491-70-2
|
Tolterodine impurity Z12
|
托特羅定Z12
|
851789-43-0
|
Tolterodine impurity Z11
|
托特羅定Z11
|
209747-04-6
|
Pantothenicacid calciumsalt impurity D
|
泛酸鈣EP-ZD
|
50692-78-9
|
Pantothenicacid calciumsalt impurity E
|
泛酸鈣EP-ZE
|
897045-90-8
|
Tolterodine impurity Z25
|
托特羅定Z25
|
109089-77-2
|
Tolterodine impurity Z17; 2-(3-amino-1-phenylpropyl)-4-methylphenol hydrochloride
|
托特羅定Z17
|
|
Pantothenicacid calciumsalt impurity G
|
泛酸鈣EP-ZG
|
2140-53-6
|
Pantothenicacid calciumsalt impurity C
|
泛酸鈣EP-ZC
|
599-04-2
|
Pantothenicacid calciumsalt impurity Z04; ethyl (R)-3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoate
|
泛酸鈣Z04
|
|
Pantothenicacid calciumsalt impurity B
|
泛酸鈣EP-ZB
|
|
Tolterodine impurity Z08
|
托特羅定Z08
|
854306-72-2
|
Tolterodine impurity D; N-isopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-amine hydrochloride
|
托特羅定EP-ZD
|
1391053-65-8
|
Tolterodine impurity Z09
|
托特羅定Z09
|
40546-94-9
|
Tolterodine impurity C
|
托特羅定EP-ZC
|
1161940-88-0
|
Tolterodine impurity A
|
托特羅定EP-ZA
|
124937-73-1
|
Tolterodine impurity Z07
|
托特羅定Z07
|
380636-49-7
|
Tolterodine impurity G
|
托特羅定EP-ZG
|
1554029-91-2
|
Milrinone impurity Z07
|
米力農(nóng)Z07
|
106637-42-7
|
Milrinone impurity Z05
|
米力農(nóng)Z05
|
80047-38-7
|
Pantothenicacid calciumsalt impurity Z05
|
泛酸鈣Z05
|
505-47-5
|
Milrinone impurity Z02
|
米力農(nóng)Z02
|
717818-05-8
|
|
Krass 中間體1,G-82a
|
2936672-09-0
|
formoterol impurity E
|
福莫特羅EP-ZE
|
1616967-26-0
|
formoterol impurity A
|
福莫特羅EP-ZA
|
150513-24-9
|
formoterol impurity H
|
福莫特羅EP-ZH
|
1337876-26-2
|
formoterol impurity F
|
福莫特羅EP-ZF
|
1795129-59-7
|
formoterol impurity C
|
福莫特羅EP-ZC
|
1795135-61-3
|
Norfloxacin impurity D
|
諾氟沙星EP-ZD
|
75001-82-0
|
Norfloxacin impurity G
|
諾氟沙星EP-ZG
|
70459-04-0
|
Norfloxacin impurity H
|
諾氟沙星EP-ZH
|
105440-01-5
|
Norfloxacin impurity C
|
諾氟沙星EP-ZC
|
177554-64-2
|
formoterol impurity I
|
福莫特羅EP-ZI
|
67346-50-3
|
Norfloxacin impurity Z04
|
諾氟沙星EP-Z04
|
75001-63-7
|
formoterol impurity D
|
福莫特羅EP-ZD
|
1795133-96-8
|
formoterol impurity G
|
福莫特羅EP-ZG
|
3706-26-1
|
formoterol impurity B
|
福莫特羅EP-ZB
|
1224588-66-2
|
Norfloxacin impurity J; 6,7-bis(4-(ethoxycarbonyl)piperazin-1-yl)-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
|
諾氟沙星EP-ZJ
|
|
Norfloxacin impurity B
|
諾氟沙星EP-ZB
|
75001-77-3
|
Norfloxacin impurity A
|
諾氟沙星EP-ZA
|
68077-26-9
|
Rivaroxaban impurityK
|
利伐沙班雜質K
|
1365267-36-2
|
Rivaroxaban impurity02
|
利伐沙班雜質02
|
1879933-39-7
|
Rivaroxaban impurityJ
|
利伐沙班雜質J
|
1632463-24-1
|
Rivaroxaban impurity03
|
利伐沙班雜質03
|
1365267-37-3
|
Rivaroxaban impurity04
|
利伐沙班雜質04
|
1411775-06-8
|
Rivaroxaban impurity01;
|
利伐沙班雜質01
|
|
Rivaroxaban impurityG
|
利伐沙班雜質G
|
446292-08-6
|
Rivaroxaban impurityA
|
利伐沙班雜質A
|
865479-71-6
|
Rivaroxaban impurityH
|
利伐沙班雜質H
|
1770812-37-7
|
Rivaroxaban impurityD
|
利伐沙班雜質D
|
1365267-35-1
|
Rivaroxaban impurityB
|
利伐沙班雜質B
|
1429334-00-8
|
Rivaroxaban impurityF
|
利伐沙班雜質F
|
24065-33-6
|
Rivaroxaban impurityE
|
利伐沙班雜質E
|
1415566-28-7
|
Sitagliptin impurity A
|
西格列汀EP-ZA
|
823817-55-6
|
Sitagliptin impurity FP-C
|
西格列汀FP-C
|
1803026-58-5
|
Sitagliptin impurity C
|
西格列汀EP-ZC
|
945261-48-3
|
Sitagliptin impurity B
|
西格列汀EP-ZB
|
486460-31-5
|
Sitagliptin impurity FP-A
|
西格列汀FP-A
|
2088771-60-0
|
Sitagliptin impurity FP-D
|
西格列汀FP-D
|
1253056-18-6
|
Topiroxostat impurity 01
|
托匹司他Z01
|
2044704-74-5
|
Topiroxostat impurity 05
|
托匹司他Z05
|
31599-25-4
|
Topiroxostat impurity 06
|
托匹司他Z06
|
2044702-36-3
|
Sitagliptin impurity FP-E
|
西格列汀FP-E
|
936630-57-8
|
Topiroxostat impurity 03
|
托匹司他Z03
|
2044706-78-5
|
Topiroxostat impurity 09
|
托匹司他Z09
|
1841081-71-7
|
Topiroxostat impurity 07
|
托匹司他Z07
|
1992028-94-0
|
Topiroxostat impurity 04; 4,4'-(5,5'-(pyridine-2,4-diyl)bis(4H-1,2,4-triazole-5,3-diyl))dipyridine
|
托匹司他Z04
|
|
Topiroxostat impurity 02
|
托匹司他Z02
|
38634-05-8
|
Tolterodine impurity E
|
托特羅定EP-ZE
|
480432-14-2
|
Topiroxostat impurity 25; 4-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)picolinohydrazide
|
托匹司他Z25
|
|
Topiroxostat impurity 23
|
托匹司他Z23
|
21379-40-8
|
Rivaroxaban impurity05
|
利伐沙班雜質05
|
|
Milrinone impurity Z11
|
米力農(nóng)Z11
|
6302-03-0
|
RO5263397
|
化合物 T12745
|
1357266-05-7
|
Norfloxacin impurity Z13; 9-chloro-6-ethyl-8-fluoro-4-oxo-4,6-dihydro-2H-1l3,2l4-[1,3,2]dioxaborinino[5,6-c]quinoline-2,2-diyl diacetate
|
諾氟沙星EP-Z13
|
|
Pantothenicacid calciumsalt impurity H; 3-(5-(1-hydroxy-2-methylpropan-2-yl)-4-oxooxazolidin-3-yl)propanoic acid
|
泛酸鈣EP-ZH
|
|
Topiroxostat impurity 24; methyl 4-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)picolinate
|
托匹司他Z24
|
|
Topiroxostat impurity 28; (Z)-isonicotinohydrazonamide
|
托匹司他Z28
|
|
Topiroxostat impurity 10
|
托匹司他Z10
|
577778-82-6
|
Topiroxostat impurity 20
|
托匹司他Z20
|
161233-97-2
|
Topiroxostat impurity 22
|
托匹司他Z22
|
2050015-91-1
|
Topiroxostat impurity 18
|
托匹司他Z18
|
135048-32-7
|
Topiroxostat impurity 13
|
托匹司他Z13
|
2044706-50-3
|
Topiroxostat impurity 19
|
托匹司他Z19
|
2044706-68-3
|
Topiroxostat impurity 16
|
托匹司他Z14
|
4329-78-6
|
Topiroxostat impurity 12; 2-cyano-4-(3-(1-oxidopyridin-4-yl)-1H-1,2,4-triazol-5-yl)pyridine 1-oxide
|
托匹司他Z12
|
|
Topiroxostat impurity 17
|
托匹司他Z17
|
36770-53-3
|
Topiroxostat impurity 14
|
托匹司他Z14
|
6975-73-1
|
Topiroxostat impurity 21; 2-cyanoisonicotinamide
|
托匹司他Z21
|
98273-47-3
|
Topiroxostat impurity 11
|
托匹司他Z11
|
2044708-04-3
|
Sitagliptin impurity FP-B
|
西格列汀FP-B
|
2805078-75-3
|